Strong Growth Ahead: Acute Care Syndromic Testing Market Size To Grow At Arecord 12.9% Cagr By 2029

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

How Big Is the Acute Care Syndromic Testing Market Size Expected to Be by 2034?
The market size for acute care syndromic testing has seen a significant expansion in the past few years. The market, which was worth $4.08 billion in 2024, is projected to increase to $4.62 billion in 2025, showcasing a compound annual growth rate (CAGR) of 13.2%. Several factors have contributed to the market's growth in the historic period, including rising awareness about antimicrobial resistance, augmented government funding for infectious diseases, more considerable investment in healthcare infrastructure, enhanced attention to syndromic testing, the proliferation of telemedicine, and an increase in infectious diseases.

In the upcoming years, the market size for acute care syndromic testing is projected to experience substantial growth, reaching a value of $7.50 billion in 2029 with a compound annual growth rate (CAGR) of 12.9%. The anticipated growth during the forecast period is attributed to several key factors, including the increased occurrence of infectious diseases, greater need for quicker diagnostic services, an expanded healthcare sector, the escalating utilization of multiplex syndromic panels, and the rise in the elderly population. The forecast period is also expected to witness several significant trends, including a transition towards point-of-care testing, the incorporation of cloud-based platforms, the widespread adoption of multiplex panels, the rise of AI-enabled tools, and increased automation in the field of syndromic testing.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21078

What Are the Emerging Segments Within the Acute Care Syndromic Testing Market?
The acute care syndromic testing market covered in this report is segmented -

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

What Long-Term Drivers Are Shaping Acute Care Syndromic Testing Market Trends?
The acute care syndromic testing market is being driven by an increasing prevalence of infectious diseases. Infections, which are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, have the potential to spread among humans, animals, and the environment. Elements such as population growth, urbanization, global travel, resistance to antimicrobials, and climate change, are major factors leading to the rise in infectious diseases. This, in turn, amplifies the demand for effective preventive measures and treatments. Acute care syndromic tests play a crucial role in infectious diseases, as they can swiftly identify pathogens and co-infections via multiplex molecular diagnostics, which facilitates targeted treatment decisions. For instance, as reported by the Health Security Agency, a government agency in the UK, the influenza positivity rate escalated to 16.6% in the fourth week of February 2024, a rise from 14.0% a week before. Likewise, consultations for influenza-like illness (ILI) surged, reaching 9.8 per 100,000 people, compared to 7.5 per 100,000 the week before. Additionally, the rate of influenza hospitalizations rose to 7.63 per 100,000 from the previous 5.12 per 100,000. Therefore, the escalating prevalence of infectious diseases is fuelling the acute care syndromic testing market.

Who Are the Top Competitors in Key Acute Care Syndromic Testing Market Segments?
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.

What Acute Care Syndromic Testing Market Trends Are Gaining Traction Across Different Segments?
Leading companies within the acute care syndromic testing market are investing in technological innovation like multiplex real-time PCR (polymerase chain reaction) technology. The objective is to raise diagnosis precision, expedite the identification of pathogens, refine laboratory operations, decrease the time to get results, and better patient outcomes by facilitating appropriate and timely treatment strategies. Multiplex real-time PCR technology is a sophisticated method of molecular diagnosis that concurrently identifies and quantifies numerous pathogens or genetic targets in a single PCR reaction - this allows for a more efficient and accurate diagnostic process. For example, QIAGEN N.V., a biotechnology research company based in the Netherlands, launched the QIAstat-Dx syndromic testing product in Japan in April 2023. This product has a SARS-CoV-2 respiratory panel that can identify over 20 pathogens from just one sample. Thanks to the multiplex real-time PCR technology, it offers quick results with less work compared to individual PCR tests. By the end of 2022, more than 3,500 of these systems had been installed worldwide, assisting in disease detection for respiratory, gastrointestinal, and conditions related to meningitis. This system is available in over 100 countries, greatly increasing the global accessibility of syndromic testing.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

Which Regions Are Becoming Hubs for Acute Care Syndromic Testing Market Innovation?
North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Acute Care Syndromic Testing Market?
2. What is the CAGR expected in the Acute Care Syndromic Testing Market?
3. What Are the Key Innovations Transforming the Acute Care Syndromic Testing Industry?
4. Which Region Is Leading the Acute Care Syndromic Testing Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.